

What is claimed is:

1. A composition comprising a cyclic peptide inhibitor of LFA-1/ICAM-1 interaction, wherein said cyclic peptide inhibitor consists of 7-10 amino acids and comprises an amino acid selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54 and SEQ ID NO: 55.
2. A therapeutic package for dispensing to, or for use in dispensing to, a mammal being treated for a hematopoietic neoplastic disease, myocardial infarction, radiation injury, asthma, rheumatoid arthritis, or lymphoma metastasis, wherein said package contains in a unit dose, an amount of a cyclic peptide of 7-10 amino acids and comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54 and SEQ ID NO: 55.
3. The package of claim 2, wherein said package is formulated for intravenous administration.
4. The package of claim 2, wherein said package includes said unit dose in a dry powder form.
5. The package of claim 2, wherein said unit dose will deliver a dose from about 10 $\mu\text{g/Kg}$ to about 500 $\mu\text{g/Kg}$.
6. The package of claim 2, wherein said unit dose will deliver a dose from about 50 $\mu\text{g/Kg}$ to about 250 $\mu\text{g/Kg}$.